Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 10.31% is in line with its 5-year average of 10.55%, around the middle of its 5-year range (7.47%–11.91%).
2.37% below its 12-month average of 10.56%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
10.31%
RETURN ON ASSETS (ROA) AVG TTM
10.56%
RETURN ON ASSETS (ROA) AVG 3Y
11.14%
RETURN ON ASSETS (ROA) AVG 5Y
10.55%
RETURN ON ASSETS (ROA) AVG 10Y
8.88%
RETURN ON ASSETS (ROA) AVG 15Y
8.67%
RETURN ON ASSETS (ROA) AVG 20Y
7.94%
CURRENT VS TTM AVG
-2.37%
CURRENT VS 3Y AVG
-7.43%
CURRENT VS 5Y AVG
-2.31%
CURRENT VS 10Y AVG
+16.04%
CURRENT VS 15Y AVG
+18.89%
CURRENT VS 20Y AVG
+29.87%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+100.58%
vs the sector median at left
Agilent Technologies, Inc.
Market Cap
$41.48B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
Market Cap
$41.04B
Return on Assets (ROA)
33.11%
TTM Avg
29.29%
3Y Avg
27.30%
5Y Avg
27.52%
Market Cap
$42.67B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$42.81B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$34.80B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
Market Cap
$49.35B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$49.93B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | $41.48B | 10.31% | 10.56% | 11.14% | 10.55% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.04B | 33.11% | 29.29% | 27.30% | 27.52% |
| IQVIA Holdings Inc. (IQV)vs › | $42.67B | 4.60% | 4.82% | 4.76% | 4.01% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.81B | 1.77% | -0.35% | -1.89% | -2.43% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.80B | 14.54% | -0.12% | -10.91% | -15.37% |
| Humana Inc. (HUM)vs › | $48.40B | 2.23% | 2.52% | 4.20% | 5.49% |
| Alcon Inc. (ALC)vs › | $33.71B | 2.06% | 3.23% | 2.72% | 1.72% |
| Becton, Dickinson and Company (BDX)vs › | $49.35B | 1.85% | 3.00% | 3.04% | 2.95% |
| Edwards Lifesciences Corporation (EW)vs › | $49.93B | 7.25% | 19.91% | 18.29% | 17.04% |
| ResMed Inc. (RMD)vs › | $32.06B | 16.99% | 17.06% | 15.57% | 14.60% |
ROA
10.3%
ROE
19.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-10-31 | 10.24% |
| 2024-10-31 | 10.88% |
| 2023-10-31 | 11.52% |
| 2022-10-31 | 11.91% |
| 2021-10-31 | 11.30% |
| 2020-10-31 | 7.47% |
| 2019-10-31 | 11.33% |
| 2018-10-31 | 3.70% |
| 2017-10-31 | 8.12% |
| 2016-10-31 | 5.90% |
| 2015-10-31 | 5.36% |
| 2014-10-31 | 5.08% |
| 2013-10-31 | 6.78% |
| 2012-10-31 | 10.94% |
| 2011-10-31 | 11.17% |
| 2010-10-31 | 7.05% |
| 2009-10-31 | -0.41% |
| 2008-10-31 | 9.89% |
| 2007-10-31 | 8.45% |
| 2006-10-31 | 44.88% |
| 2005-10-31 | 2.09% |
| 2004-10-31 | 5.17% |
| 2003-10-31 | -32.68% |
| 2002-10-31 | -12.58% |
| 2001-10-31 | 2.10% |
| 2000-10-31 | 9.09% |
| 1999-10-31 | 9.40% |
| 1998-10-31 | 5.15% |
